Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Aktuelle Urol[TA])
1,520 results
  • [Pre-, intra- and postoperative predictors of functional outcome following radical prostatectomy]. [Journal Article]
    Aktuelle Urol. 2020 Jun 25 [Online ahead of print]Krausewitz P, Ritter M
  • Maintaining continence and erectile function is crucial for quality of life after radical prostatectomy. This review provides an overview of available evidence concerning preoperative risk stratification as well as intra- and postoperative factors determining functional outcomes after radical prostatectomy.Current data indicate that patient factors including age, baseline erectile function, prost…
  • [The impact of radical cystectomy on health-related quality of life and potential for optimisation]. [Journal Article]
    Aktuelle Urol. 2020 Jun 24 [Online ahead of print]Rudolph J, Martini T, Wezel F
  • Radical cystectomy may have a major impact on the lives of affected patients. Older patients often have a reduced life expectancy after radical cystectomy. Therefore, aspects of health-related quality of life (HRQOL) have to be balanced against a solely tumour-directed therapy. In this narrative review, factors influencing the HRQOL of affected patients were identified and discussed by selective …
  • [Bladder hernia: report of a case series and review of the literature]. [Journal Article]
    Aktuelle Urol. 2020 Jun 18 [Online ahead of print]Trenti E, Palermo S, … Comploj E
  • Inguinal bladder hernia accounts for only 1 - 4 % of all inguinal hernias. It may be difficult to diagnose due to the atypical symptoms. In most cases, the diagnosis is only made intraoperatively. However, a preoperative diagnosis is important to avoid possible iatrogenic complications. We report a case series of five patients with the rare pathology of bladder hernia treated in our department in…
  • [Prostate cancer: surgical complications]. [Journal Article]
    Aktuelle Urol. 2020 Jun 17 [Online ahead of print]Haidl F, Al-Monajjed R
  • Radical prostatectomy (RP), performed as an open, laparoscopic or robotic procedure, remains the "gold standard" for patients with localised prostate cancer who can be cured with surgery and have a life expectancy of at least 10 years. Today, RP is also used as a first-line treatment for locally advanced prostate cancer, possibly in a multimodal setting with adjuvant radiation/hormonal therapy. T…
  • [Potential for improvement by new resection and imaging techniques in TUR-B]. [Journal Article]
    Aktuelle Urol. 2020 Jun 10 [Online ahead of print]Hennig MJP, Kramer MW
  • Transurethral resection of bladder tumors (TURB) is the cornerstone in urological care of bladder cancer patients. Since the introduction of resectoscopes almost 100 years ago, little has changed in the basic resection technique. The further dissemination of the en-bloc resection (ERBT), which in contrast to fragmented removal preserves the tumor's integrity, might re-adjust the surgical landscap…
  • [Bladder cancer - complications related to urinary diversion]. [Journal Article]
    Aktuelle Urol. 2020 May 27 [Online ahead of print]Pfister D, Niegisch G
  • Even today, radical cystectomy with urinary diversion is one of the most complicated procedures in uro-oncology. Particularly in the long-term course, but also perioperatively, problems caused by urinary diversion play a significant role.Perioperatively, gastrointestinal problems such as an ileus, but also infections and early complications of the different anastomoses are most important. While i…
  • [Treatment of the primary tumour in oligometastatic prostate cancer]. [Journal Article]
    Aktuelle Urol. 2020 06; 51(3):252-257.Bottke D, Wiegel T
  • In the treatment of metastatic prostate cancer, significant improvements have recently been made. In addition to androgen deprivation, various options are available, such as anti-androgen receptor therapies with abiraterone and enzalutamide and taxane-based chemotherapy. It is still being discussed whether oligometastatic patients should only be treated systemically, or whether they benefit from …
  • [Surgical treatment of pulmonary metastases in metastatic renal cell carcinoma]. [Journal Article]
    Aktuelle Urol. 2020 06; 51(3):271-274.Gilbert N
  • Between 20 and 30 % of patients diagnosed with renal cell carcinoma suffer from metastatic disease by the time of diagnosis and a further 20 - 30 % develop metachronous metastases after initial treatment with curative intent. The therapeutic landscape of metastatic renal cell carcinoma seems be changing rapidly, with new systemic therapies or combination therapies available and established concep…
  • [Surgery only? Multimodal treatment for urothelial carcinoma of the bladder]. [Journal Article]
    Aktuelle Urol. 2020 Apr 14 [Online ahead of print]Schuettfort V, Shariat SF, Rink M
  • Radical cystectomy is the gold standard in treatment of muscle invasive bladder carcinoma. Especially for patients with advanced tumours, multimodal therapies play an important role in optimising patient care. In older patients with multiple comorbidities, who are not eligible for surgery, alternative treatment modalities are needed as well. This article summarises the current literature on multi…
  • [Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy]. [Journal Article]
    Aktuelle Urol. 2020 Apr 08 [Online ahead of print]Merseburger AS, Rüssel C, … Bögemann M
  • CONCLUSIONS: In contrast to the new definition of castration resistance, AA + P was still more frequently used in daily clinical practice during the study observation period in patients treated with antiandrogens of the first generation after occurrence of castration resistance. Nevertheless, AA + P therapy appears to be effective and well tolerated during clinical routine in mCRPC patients. A comparison of the study results with earlier 'real-world' studies, however, has to take limiting factors into account. The observed difference in median overall survival might be explained by the imbalance of baseline characteristics between both cohorts with regard to number of patients, patients already deceased at start of documentation, patients with visceral metastases and patients with opioids at start of AA + P. For these reasons, patients in the EC initially might have had a poorer prognosis. A prospective randomised and controlled clinical trial would therefore be necessary to assess a possible difference in overall survival and response of the AA + P treatment with respect to therapy onset.
New Search Next